(Q37366765)

20 August 2017

Assessment of linezolid efficacy, safety and tolerability in the treatment of tuberculosis: A retrospective case review (English)

1 reference

20 August 2017

0 references

1 reference

Alena Tse-Chang

1

1 reference

20 August 2017

Dennis Kunimoto

series ordinal

2

1 reference

20 August 2017

Evelina Der

series ordinal

3

1 reference

20 August 2017

Rabia Ahmed

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 January 2013

1 reference

Canadian Journal of Infectious Diseases & Medical Microbiology

20 August 2017

1 reference

20 August 2017

24

1 reference

20 August 2017

3

1 reference

20 August 2017

e50-2

1 reference

Creative Commons Attribution 4.0 International

20 August 2017

start time

1 January 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Linezolid for the treatment of multidrug-resistant tuberculosis

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Linezolid in the treatment of MDR-TB: a retrospective clinical study

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Linezolid in the treatment of 'difficult' multidrug-resistant tuberculosis

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3852456

Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24421829

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24421829

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2013/535616

1 reference

20 August 2017

1 reference

20 August 2017

1 reference